Community-Acquired Bacterial Pneumonia
&nbsp;
Community-acquired bacterial pneumonia (CABP) is a common, acute, severe infection of the lung parenchyma. It is a major cause of mortality in adults. It is one of the most frequent respiratory illnesses among various infections triggering sepsis. The Global Burden of Disease Study identified lower respiratory tract infection (LRTI) as the second most common cause of death and years of life lost. Microbiologically, bacteria are common agents in pneumonia, with Streptococcus pneumoniae being the most common cause worldwide.
&nbsp;
Community-Acquired Bacterial Pneumonia Epidemiology Segmentation in the 7MM
&nbsp;
<ul>
<li class="ql-align-justify">Incident Cases of Community-Acquired Bacterial Pneumonia (CABP)</li>
<li class="ql-align-justify">Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) based on Gender</li>
<li class="ql-align-justify">Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) based on Severity</li>
<li class="ql-align-justify">Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens</li>
<li class="ql-align-justify">Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) based on Age</li>
</ul>
&nbsp;
&nbsp;
&nbsp;
<a style="background-color: transparent; color: #111111;" href="https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Community-Acquired Bacterial Pneumonia Epidemiological Insights</a> Observed in the 7MM
(2021)
&nbsp;
<ul>
<li class="ql-align-justify">The total prevalent cases of Community-Acquired Bacterial Pneumonia observed in the 7MM were observed to be 6.8 million in the year 2021</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #111111;" href="https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market" target="_blank" rel="noopener noreferrer">Community-Acquired Bacterial Pneumonia Market Insight</a>
&nbsp;
The market size of Community-Acquired Bacterial Pneumonia in the 7MM was found to be approximately USD 2,866 million in 2021.
&nbsp;
<a style="background-color: transparent; color: #111111;" href="https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-pipeline-insight" target="_blank" rel="noopener noreferrer">Community-Acquired Bacterial Pneumonia Emerging Drug</a>s
&nbsp;
The emerging drugs in the Community-Acquired Bacterial Pneumonia market are
<ul>
<li class="ql-align-justify">&nbsp;</li>
<li class="ql-align-justify">CAL02</li>
<li class="ql-align-justify">Cx611, and others</li>
</ul>
&nbsp;
Community-Acquired Bacterial Pneumonia Key Players&nbsp;
&nbsp;
The key players working in the Community-Acquired Bacterial Pneumonia market are
&nbsp;
<ul>
<li class="ql-align-justify">Eagle Pharmaceutical Inc.</li>
<li class="ql-align-justify">Combioxin SA</li>
<li class="ql-align-justify">Takeda</li>
<li class="ql-align-justify">TiGenix, and others</li>
</ul>
&nbsp;

Community Acquired Bacterial Pneumonia

Community Acquired Bacterial Pneumonia Market

Community-Acquired Bacterial Pneumonia Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape